| Budget Amount *help |
¥17,290,000 (Direct Cost: ¥13,300,000、Indirect Cost: ¥3,990,000)
Fiscal Year 2021: ¥3,380,000 (Direct Cost: ¥2,600,000、Indirect Cost: ¥780,000)
Fiscal Year 2020: ¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2019: ¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2018: ¥5,590,000 (Direct Cost: ¥4,300,000、Indirect Cost: ¥1,290,000)
|
|---|
| Outline of Final Research Achievements |
Based on the combination of immunoprecipitation and mass spectrometry analysis of human serum and cultured human cells, we identified C-C motif chemokine 2 (CCL2) and Frizzled (FZD) as novel adiponectin binding proteins.
We found that the percentage of plaque in the coronary culprit lesions was negatively correlated with serum adiponectin levels and positively correlated with serum CCL2 levels, with significance, in male patients with stable angina. The anti-atherogenic property of adiponectin-CCL2 binding was functionally demonstrated by the inhibition of monocyte migration and MAP kinase phosphorylation, and these mechanisms could explain the clinical findings. In addition, we speculated that adiponectin can compete Wnt-mediated pro-atherogenic signals through the direct binding of FZD.
|
